Immunoprecise Antibodies Ltd Share Price Other OTC
Equities
CA87588T1030
Pharmaceuticals
Sales 2024 * | 24.59M 17.95M 1.5B | Sales 2025 * | 29.82M 21.77M 1.82B | Capitalization | 35.94M 26.23M 2.19B |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.76M -732M | Net income 2025 * | -9M -6.57M -549M | EV / Sales 2024 * | 1.46 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.21 x |
P/E ratio 2024 * |
-2.85
x | P/E ratio 2025 * |
-3.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/18/21 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/23/29 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/23/05 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/18/21 |
1st Jan change | Capi. | |
---|---|---|
+2.87% | 94.22B | |
-4.08% | 37.76B | |
-13.43% | 32.5B | |
+73.38% | 27.75B | |
-11.45% | 16.13B | |
-0.38% | 14.19B | |
-11.67% | 11.42B | |
+190.36% | 11.06B | |
-52.61% | 9.09B |